A Phase 2a Double Blind, Randomized, Placebo-Controlled Trial Evaluating Two Dose Levels of CIT-013 for Hidradenitis Suppurativa

What this Trial Is About

Researchers are evaluating the effects of CIT-013 in adults with Hidradenitis Suppurativa (HS), a chronic skin condition. This Phase 2a randomized, double-blind, placebo-controlled trial aims to find out if CIT-013 can reduce disease activity and to assess its safety. The study compares two doses of CIT-013 to a placebo to understand its impact on symptoms and medical issues experienced by participants. Participants will receive either a high dose (100 mg) or medium dose (50 mg) of CIT-013, or a placebo, through subcutaneous injections every other week for 12 weeks. The treatments involve six injections in total. The trial includes three groups: one for each dose of CIT-013 and one for the placebo, all administered via injections under the skin. During the study, participants will visit the clinic every two weeks for checkups and tests. Researchers will monitor symptoms, measure disease activity using the HiSCR75 response at week 12, and track any treatment-related adverse events. Blood samples will be taken at various points to assess drug levels. The total study participation lasts for 12 weeks with regular monitoring throughout this period.

A Study With CIT-013 in HS Patients